Peptide
Ipamorelin
A selective growth hormone releasing peptide (GHRP) that binds the ghrelin receptor. Cleaner side effect profile than earlier GHRPs. Widely paired with CJC-1295 in anti-aging clinics.
Summary What is ipamorelin, and does it help with healthy aging? Show / hide ↓
Ipamorelin is an injectable peptide, a small chain of amino acids, that tells the body to release more growth hormone, a hormone involved in growth and tissue repair. It mainly acts on the ghrelin receptor, a cell switch linked to growth hormone release, and usually does not strongly increase hunger, cortisol, or prolactin. It was studied for post-operative ileus, a delayed return of bowel movement after surgery, but the program ended after modest results and was not advanced to larger trials. Clinics often combine it with CJC-1295 or similar drugs, which can raise growth hormone and IGF-1, a growth-related blood marker, but no controlled human trials show meaningful age-related benefits. Short-term safety reports suggest mostly mild problems, such as reactions where it is injected, but the long-term effects of keeping growth hormone and IGF-1 high are uncertain, including a theoretical cancer concern.
What this means for you: Ipamorelin may raise growth hormone, but that does not prove it slows aging or improves health. There is not enough reliable human evidence to recommend buying it for longevity.
weak evidenceIpamorelin is the cleanest of the classical GH-releasing peptides. Novo Nordisk developed it in the 1990s and 2000s, primarily for post-operative ileus (delayed return of gut motility after abdominal surgery). Phase 2 trials showed modest efficacy but not enough to move to phase 3, and Novo Nordisk shelved the program.
The pharmacology is well-characterized. Ipamorelin activates the same receptor as ghrelin, driving pulsatile GH release from the pituitary. Unlike ghrelin itself, ipamorelin does not stimulate appetite meaningfully at typical doses. Unlike earlier GHRPs, ipamorelin does not raise cortisol or prolactin at therapeutic doses, which is its key selling point.
In the anti-aging community, ipamorelin is almost always used in combination with a GHRH analog (CJC-1295 without DAC, or Mod-GRF 1-29, or tesamorelin) rather than alone. The theoretical basis is receptor synergy: GHRH raises the amplitude of pituitary GH pulses, while a GHRP raises the frequency. The combined effect is meaningfully larger than either alone. This is textbook pituitary endocrinology, and it works in the sense that measured GH and IGF-1 rise more with the combination.
Whether that translates to meaningful long-term benefits (reduced visceral fat, better body composition, better recovery, better sleep) at the doses users take is not settled. Placebo-controlled trials of ipamorelin plus CJC-1295 with age-related endpoints do not exist. Anecdotal reports from anti-aging clinics are broadly positive but do not substitute for controlled data.
The safety profile at short-term community doses is good. Ipamorelin does not raise cortisol or prolactin meaningfully, water retention is mild, injection site reactions are the main complaint. Long-term (multi-year) sustained elevation of GH and IGF-1 raises the same theoretical cancer surveillance concern as with any GH-secretagogue.
Our position: Ipamorelin sits at Tier 5. Best-tolerated of the classical GHRPs. No completed modern age-related human trials. Community use rests on physiologic mechanism and user reports rather than outcome data.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.